Left ventricular hypertrophy: Virtuous intentions, malign consequences

International Journal of Biochemistry and Cell Biology

Volumn 35, Issue 6, 2003, Pages 802-806

  Pokharel, Saraswati ^a   Sharma, Umesh C ^a   Pinto, Yigal M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Heart failure; Hypertrophy; Neurohormone

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; LOSARTAN; NEUROHORMONE; NORADRENALIN; VASODILATOR AGENT;

CALCIUM HOMEOSTASIS; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CYTOSKELETON; DISEASE COURSE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HORMONE INHIBITION; HUMAN; MORBIDITY; MORTALITY; MYOFILAMENT; NEUROENDOCRINE SYSTEM; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 0037409236     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(02)00344-8     Document Type: Short Survey

References (12)

1. Cotran, S. R. K. V., & Collins, T. (1999). Cardiac hypertrophy: pathophysiology and progression to failure. Robbins pathologic basis of disease (6th ed.) (pp. 547-549).
2. Harada K., Komuro I., Shiojima I., Hayashi D., Kudoh S., Mizuno T., Kizima K., Matsubara H., Sugaya T., Murakami K., Yazaki Y. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation. 97(19):1998;1952-1959.
3. Hunter J.J., Chien K.R. Signalling pathways for cardiac hypertrophy and failure. New England Journal of Medicine. 341(17):1999;1276-1283.
4. Li J.M., Gall N.P., Grieve D.J., Chen M., Shah M. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 40(4):2002;477-484.
5. Lorell B.H., Carabello B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 102(4):2000;470-479.
6. Mann D.L. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 100(9):1999;999-1008.
7. Pinto Y.M., Paul M., Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovascular Research. 39(1):1998;77-88.
8. Pinto Y.M.et al. Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen-2)27 Rat. Hypertension. 36(5):2000;747-754.
9. Schirmer H., Lunde P., Rasmussen K. Prevalence of left ventricular hypertrophy in a general population: the Tromso Study. European Heart Journal. 20(6):1999;429-438.
10. Schunkert H.et al. Association between a deletion polymorphism of the angiotensin-converting enzyme gene and left ventricular hypertrophy. New England Journal of Medicine. 330(23):1994;1634-1638.
11. van Zwieten P.A. The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy. Cardiovascular Research. 45(1):2000;82-91.
12. Villari B., Vassalli G., Monrad E.S., Chiariello M., Turina M., Hess O.M. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation. 91(9):1995;2353-2358.